Cargando…

Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action

BACKGROUND: Health technology assessment (HTA) agencies have an important role in the evaluation and approval of new technologies. They determine their value within a health system so to promote equitable, quality care with available healthcare resources. Many HTA agencies have some mechanism for in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wale, Janet L., Thomas, Samuel, Hamerlijnck, Dominique, Hollander, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783693/
https://www.ncbi.nlm.nih.gov/pubmed/33402216
http://dx.doi.org/10.1186/s40900-020-00248-9
_version_ 1783632160895270912
author Wale, Janet L.
Thomas, Samuel
Hamerlijnck, Dominique
Hollander, Ronald
author_facet Wale, Janet L.
Thomas, Samuel
Hamerlijnck, Dominique
Hollander, Ronald
author_sort Wale, Janet L.
collection PubMed
description BACKGROUND: Health technology assessment (HTA) agencies have an important role in the evaluation and approval of new technologies. They determine their value within a health system so to promote equitable, quality care with available healthcare resources. Many HTA agencies have some mechanism for involving patients in their processes, but there is great variability and an absence of comprehensive, robust practices for involvement. The accelerating pace of medical innovation creates a need to improve the depth and breadth of patient involvement in the HTA process. MAIN BODY: In this ‘Call to action’, we present ideas from three HTA expert commentaries calling for collaborative learning and to share innovative ideas for changes in HTA. We also draw on examples of HTA agencies creatively pursuing this goal. We propose a ‘Call to action’ for HTA stakeholders to undertake serious dialogue with patient advocates aimed at creating shared goals. HTA agencies can use these goals to ensure meaningful patient involvement at every step of the HTA process. Five elements are explored. In ‘Recognizing the value of shared purpose’, we highlight examples of HTA agencies that have patients working in partnership with medical practitioners and HTA staff. Results include improved processes that instil confidence. ‘Committing to patient involvement as part of HTA culture’ highlights several initiatives aimed at changes in HTA organisational culture to be more inclusive of patients. In ‘Aligning patient and HTA goals’ we cite work in Belgium and New Zealand which places a greater emphasis on quality of life rather than life expectancy and cost-effectiveness. By ‘Integrating patient involvement at every step of the HTA process’ patients can make vital contributions at every stage of the HTA process. We provide two examples of where HTA agencies have successfully involved patients early in the process in order to broaden the scope of evaluations. ‘Developing a common language and working together’ can support transformative dialogue through ‘unified language’. CONCLUSION: The authors of this commentary ask that agencies and stakeholders involved in HTA take up this call to work together for visionary and transformative elevation of the voice of patients in HTA worldwide.
format Online
Article
Text
id pubmed-7783693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77836932021-01-05 Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action Wale, Janet L. Thomas, Samuel Hamerlijnck, Dominique Hollander, Ronald Res Involv Engagem Commentary BACKGROUND: Health technology assessment (HTA) agencies have an important role in the evaluation and approval of new technologies. They determine their value within a health system so to promote equitable, quality care with available healthcare resources. Many HTA agencies have some mechanism for involving patients in their processes, but there is great variability and an absence of comprehensive, robust practices for involvement. The accelerating pace of medical innovation creates a need to improve the depth and breadth of patient involvement in the HTA process. MAIN BODY: In this ‘Call to action’, we present ideas from three HTA expert commentaries calling for collaborative learning and to share innovative ideas for changes in HTA. We also draw on examples of HTA agencies creatively pursuing this goal. We propose a ‘Call to action’ for HTA stakeholders to undertake serious dialogue with patient advocates aimed at creating shared goals. HTA agencies can use these goals to ensure meaningful patient involvement at every step of the HTA process. Five elements are explored. In ‘Recognizing the value of shared purpose’, we highlight examples of HTA agencies that have patients working in partnership with medical practitioners and HTA staff. Results include improved processes that instil confidence. ‘Committing to patient involvement as part of HTA culture’ highlights several initiatives aimed at changes in HTA organisational culture to be more inclusive of patients. In ‘Aligning patient and HTA goals’ we cite work in Belgium and New Zealand which places a greater emphasis on quality of life rather than life expectancy and cost-effectiveness. By ‘Integrating patient involvement at every step of the HTA process’ patients can make vital contributions at every stage of the HTA process. We provide two examples of where HTA agencies have successfully involved patients early in the process in order to broaden the scope of evaluations. ‘Developing a common language and working together’ can support transformative dialogue through ‘unified language’. CONCLUSION: The authors of this commentary ask that agencies and stakeholders involved in HTA take up this call to work together for visionary and transformative elevation of the voice of patients in HTA worldwide. BioMed Central 2021-01-05 /pmc/articles/PMC7783693/ /pubmed/33402216 http://dx.doi.org/10.1186/s40900-020-00248-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Wale, Janet L.
Thomas, Samuel
Hamerlijnck, Dominique
Hollander, Ronald
Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
title Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
title_full Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
title_fullStr Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
title_full_unstemmed Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
title_short Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
title_sort patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783693/
https://www.ncbi.nlm.nih.gov/pubmed/33402216
http://dx.doi.org/10.1186/s40900-020-00248-9
work_keys_str_mv AT walejanetl patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction
AT thomassamuel patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction
AT hamerlijnckdominique patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction
AT hollanderronald patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction